At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
Department and Institute of Infectious Disease
Wuhan, Hubei, China
RECRUITINGRate of disease remission
For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2\>93% or PaO2/FiO2 \>300mmHg.
Time frame: day 7
Rate and time of entering the critical stage
the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment.
Time frame: day 7
Rate of normal tempreture
Rate of patients without fever at day 7
Time frame: day 7
Rate of respiratory symptom remission
Rate of patients with respiratory symptom remission at day 7
Time frame: day 7
Rate of lung imaging recovery
Rate of patients with lung imaging recovery at day 7
Time frame: day 7
Rate of laboratory indicator recovery
Rate of patients with laboratory indicator recovery at day 7
Time frame: day 7
Rate of undetectable viral RNA
Rate of patients withundetectable viral RNA at day 7
Time frame: day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.